Volume 15, Issue 59 (7-2025)
NCMBJ 2025, 15(59): 73-86 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Sadatfar S M, Issazadeh K, Habibi A. Effect of iron oxide nanoparticles functionalized with hyaluronic acid on CD44 gene expression and growth of Aspc-1 cell line of pancreatic cancer. NCMBJ 2025; 15 (59) :73-86
URL: http://ncmbjpiau.ir/article-1-1770-en.html
URL: http://ncmbjpiau.ir/article-1-1770-en.html
Assistant Professor, Department of Basic Sciences, Science Higher Education Center, Imam Hossein (AS) Officer Training and Guards University, Tehran, Iran , alirh110@gmail.com
Abstract: (9 Views)
Aim and Background: Pancreatic cancer is the third leading cause of cancer-related mortality. The utilization of hyaluronic acid in treatment is promising due to its targeted absorption and lack of adverse effects. The objective of this study was to examine the impact of iron oxide and hyaluronic nanoparticles on alterations in CD44 gene expression within cancer cells.
Materials and Methods: Iron oxide nanoparticles were synthesized using the co-precipitation method and then functionalized with hyaluronic acid in this study. Various confirmatory tests, such as Scanning Electron Microscopy (SEM), Fourier Transform Infrared Spectroscopy (FTIR), Energy Dispersive X-Ray (EDX), Ultraviolet-Visible (UV-visible), and Zeta-potential, were conducted for characterization purposes. The viability of ASPC-1 and HEK-293 cells post-treatment with Fe3O4@HA was assessed using the MTT method. Additionally, the expression of the CD44 gene in both treated and control cells was analyzed through the qRT-PCR technique.
Results: The Fe3O4@HA complex exhibited a more potent impact on ASPC-1 cells compared to Fe3O4 (P < 0.05), while its effect on normal cells was less pronounced (P > 0.05). The Selectivity Index (SI) for drug selection was determined to be 1.13. Analysis of qRTPCR data revealed a 6% decrease in CD44 expression in treated cells at the IC50 concentration, although this difference was not statistically significant (P > 0.05).
Conclusion: In conclusion, the outcomes of this investigation demonstrate that Fe3O4@HA possesses effective anti-proliferative characteristics against pancreatic cancer cells and has the ability to lower CD44 gene expression.
Materials and Methods: Iron oxide nanoparticles were synthesized using the co-precipitation method and then functionalized with hyaluronic acid in this study. Various confirmatory tests, such as Scanning Electron Microscopy (SEM), Fourier Transform Infrared Spectroscopy (FTIR), Energy Dispersive X-Ray (EDX), Ultraviolet-Visible (UV-visible), and Zeta-potential, were conducted for characterization purposes. The viability of ASPC-1 and HEK-293 cells post-treatment with Fe3O4@HA was assessed using the MTT method. Additionally, the expression of the CD44 gene in both treated and control cells was analyzed through the qRT-PCR technique.
Results: The Fe3O4@HA complex exhibited a more potent impact on ASPC-1 cells compared to Fe3O4 (P < 0.05), while its effect on normal cells was less pronounced (P > 0.05). The Selectivity Index (SI) for drug selection was determined to be 1.13. Analysis of qRTPCR data revealed a 6% decrease in CD44 expression in treated cells at the IC50 concentration, although this difference was not statistically significant (P > 0.05).
Conclusion: In conclusion, the outcomes of this investigation demonstrate that Fe3O4@HA possesses effective anti-proliferative characteristics against pancreatic cancer cells and has the ability to lower CD44 gene expression.
Type of Study: Research Article |
Subject:
Cellular and molecular
Received: 2025/09/9 | Accepted: 2025/07/1 | Published: 2025/07/1
Received: 2025/09/9 | Accepted: 2025/07/1 | Published: 2025/07/1
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
